SPPI Spectrum Pharmaceuticals Inc.

3.6
-0.14  -4%
Previous Close 3.74
Open 3.73
52 Week Low 1.7422
52 Week High 5.24
Market Cap $525,319,942
Shares 145,922,206
Float 111,247,031
Enterprise Value $335,960,051
Volume 2,361,589
Av. Daily Volume 2,392,040
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
SPI-2012 (ROLONTIS)
Chemotherapy-Induced Neutropenia
PDUFA
PDUFA
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Poziotinib
Non-small cell lung cancer (NSCLC) with exon 20 insertion mutation in EGFR or HER2
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Belinostat
Peripheral T-Cell Lymphoma cancer
Approved
Approved
Approved July 7, 2014.
EVOMELA (melphalan) for Injection
Conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma
Approved
Approved
CRL October 23 2015. Approved March 15 2016.
FUSILEV
Colorectal cancer
Approved
Approved
CRL received October 9, 2009. Approved April 29, 2011.
ZEVALIN
Non-Hodgkin’s lymphoma
CRL
CRL
CRL received July 5, 2009.

Latest News

  1. Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on interim safety evaluation of same-day dosing of ROLONTIS® (eflapegrastim) in patients with early-stage breast cancer receiving docetaxel and cyclophosphamide. This presentation will take place as part of the 38th Annual Miami Breast Cancer Conference® taking place virtually March 4-7, 2021. Details of the presentation are as follows:

    Title: Interim safety evaluation of same-day dosing of eflapegrastim in patients with early-stage breast cancer (ESBC) receiving docetaxel and cyclophosphamide (TC)
    Speaker: Lee S. Schwartzberg. M.D., FACP
    Session: Poster Presentation
    Date and Time: March…

    Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on interim safety evaluation of same-day dosing of ROLONTIS® (eflapegrastim) in patients with early-stage breast cancer receiving docetaxel and cyclophosphamide. This presentation will take place as part of the 38th Annual Miami Breast Cancer Conference® taking place virtually March 4-7, 2021. Details of the presentation are as follows:

    Title: Interim safety evaluation of same-day dosing of eflapegrastim in patients with early-stage breast cancer (ESBC) receiving docetaxel and cyclophosphamide (TC)

    Speaker: Lee S. Schwartzberg. M.D., FACP

    Session: Poster Presentation

    Date and Time: March 4, 2021, 6:00pm EST

    Access to the presentations is available to members of Physicians Education Resource (PER®) and can be found here: https://www.gotoper.com/conferences/mbcc/meetings/38th-annual-miami-breast-cancer-conference.

    About Spectrum Pharmaceuticals, Inc.

    Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com.

    Forward-looking statement — This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum's business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum's existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

    SPECTRUM PHARMACEUTICALS, INC.® and ROLONTIS® are registered trademarks of Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

    © 2021 Spectrum Pharmaceuticals, Inc. All Rights Reserved

    View Full Article Hide Full Article
  2. Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced two presentations, one oral and one eposter, at the upcoming European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual Congress 2021. The oral presentation will provide some initial safety and efficacy data for poziotinib from the twice daily dosing cohort. The meeting takes place on March 1 – 2, 2021. Details of the presentations are as follows:

    Title: IGN002 (antiCD20-IFNα2b) intravenously administered tumor targeted delivery of IFNα2b and its effects in non-Hodgkin lymphoma
    Speaker: Sribalaji Lakshmikanthan, Ph.D.
    Session: Immunotherapy (ID 361)
    Date and Time:
    March 1, 2021…

    Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced two presentations, one oral and one eposter, at the upcoming European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual Congress 2021. The oral presentation will provide some initial safety and efficacy data for poziotinib from the twice daily dosing cohort. The meeting takes place on March 1 – 2, 2021. Details of the presentations are as follows:

    Title: IGN002 (antiCD20-IFNα2b) intravenously administered tumor targeted delivery of IFNα2b and its effects in non-Hodgkin lymphoma

    Speaker: Sribalaji Lakshmikanthan, Ph.D.

    Session: Immunotherapy (ID 361)

    Date and Time:
    March 1, 2021, 9:41 a.m. CET / 3:41 a.m. ET

    Presentation Number:
    #20P (poster)

    Title: Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer

    Speaker: Adrian Sacher, M.D.

    Session: Mini Oral Session (ID 17) Channel 1

    Date and Time: March 2, 2021, 17:25 CET / 11:25 a.m. ET

    Presentation Number: 36MO (mini-oral)

    Access to the presentations is available to members of ESMO and can be found here: https://cslide.ctimeetingtech.com/tat2021/signin?back=%2Ftat2021%2Fattendee%2Fconfcal%2Fsession%2Fcalendar&module=attendee#signin

    About Spectrum Pharmaceuticals, Inc.

    Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com.

    Forward-looking statement — This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum's business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum's existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

    SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc. and its affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

    © 2021 Spectrum Pharmaceuticals, Inc. All Rights Reserved

    View Full Article Hide Full Article
  3. Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day. The fireside chat is scheduled for Thursday, February 11, 2021, at 4 p.m. EST.

    A live webcast of the fireside chat will be available from the Investor Relations section of the company's website at http://investor.sppirx.com/events-and-presentations with a replay available shortly after the event.

    About Spectrum Pharmaceuticals, Inc.

    Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong…

    Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day. The fireside chat is scheduled for Thursday, February 11, 2021, at 4 p.m. EST.

    A live webcast of the fireside chat will be available from the Investor Relations section of the company's website at http://investor.sppirx.com/events-and-presentations with a replay available shortly after the event.

    About Spectrum Pharmaceuticals, Inc.

    Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals, please visit www.sppirx.com.

    Forward-looking statement — This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum's business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum's existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

    SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

    © 2021 Spectrum Pharmaceuticals, Inc. All Rights Reserved

    View Full Article Hide Full Article
  4. Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on updated efficacy, safety, and dosing management of poziotinib from Cohorts 1 and 2 of the ZENITH20 clinical trial. In addition, Spectrum also announced an oral presentation on the structural classification of atypical EGFR mutations and their patterns of drug sensitivity. These presentations will take place as part of the IASLC 2020 World Conference on Lung Cancer (#WCLC20) hosted by the International Association for the Study of Lung Cancer (IASLC) taking place virtually January 28-31, 2021. Details of the presentations are as follows:

    Title: Updated efficacy, safety, and dosing management…

    Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on updated efficacy, safety, and dosing management of poziotinib from Cohorts 1 and 2 of the ZENITH20 clinical trial. In addition, Spectrum also announced an oral presentation on the structural classification of atypical EGFR mutations and their patterns of drug sensitivity. These presentations will take place as part of the IASLC 2020 World Conference on Lung Cancer (#WCLC20) hosted by the International Association for the Study of Lung Cancer (IASLC) taking place virtually January 28-31, 2021. Details of the presentations are as follows:

    Title: Updated efficacy, safety, and dosing management of poziotinib in previously treated EGFR and HER2 exon 20 NSCLC patients

    Speaker: Robin Cornelissen, Ph.D., M.D.

    Session: Expanding Targetable Genetic Alterations in NSCLC Mini Oral Session

    Date and Time: January 31, 2021, 14:20 SGT (January 30, 2021 10:20 p.m. PT)

    Presentation Number: MA11.04

    Title: Structural classification of atypical EGFR mutations identifies four major subgroups with distinct patterns of drug sensitivity

    Speaker: Jacqulyne P. Robichaux. Ph.D.

    Session: Tumor Biology: Focus on EGFR Mutation, DNA Repair and Tumor Microenvironment Mini Oral Session

    Date and Time: January 31, 2021, 17:20 SGT (January 31, 2021 1:20 a.m. PT)

    Presentation Number: MA13.07

    Access to the presentations is available to members of IASLC and can be found here: https://wclc2020.iaslc.org/registration/.

    About Spectrum Pharmaceuticals, Inc.

    Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com.

    Forward-looking statement — This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum's business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum's existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

    SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

    © 2021 Spectrum Pharmaceuticals, Inc. All Rights Reserved

    View Full Article Hide Full Article
  5. Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will provide an overview of the company's business strategy and development-stage programs at three upcoming virtual investor conferences:

    • H.C. Wainwright BioConnect Conference, a fireside chat will be available on-demand through the conference portal and on the Spectrum corporate website beginning Monday, January 11th at 6 a.m. ET.
    • ICR Conference 2021, presentation, live webcast, Thursday, January 14th at 1:45 p.m. ET.
    • B. Riley Oncology Investor Conference, fireside chat, live webcast, Thursday, January 21st at 1 p.m. ET.

    These events will be available from the Investor Relations section…

    Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will provide an overview of the company's business strategy and development-stage programs at three upcoming virtual investor conferences:

    • H.C. Wainwright BioConnect Conference, a fireside chat will be available on-demand through the conference portal and on the Spectrum corporate website beginning Monday, January 11th at 6 a.m. ET.
    • ICR Conference 2021, presentation, live webcast, Thursday, January 14th at 1:45 p.m. ET.
    • B. Riley Oncology Investor Conference, fireside chat, live webcast, Thursday, January 21st at 1 p.m. ET.

    These events will be available from the Investor Relations section of the company's website at http://investor.sppirx.com/events-and-presentations. An archived webcast will be available shortly after the ICR and B. Riley live events from the same website location.

    About Spectrum Pharmaceuticals, Inc.

    Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com.

    Forward-looking statement — This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum's business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum's existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

    SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

    © 2021 Spectrum Pharmaceuticals, Inc. All Rights Reserved

    View Full Article Hide Full Article
View All Spectrum Pharmaceuticals Inc. News